BD affects millions but remains misunderstood, underdiagnosed, and underfunded. Researchers are working to change this by ...
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.BoQAct6R.js ...
Eli Lilly reported mixed results for the fourth quarter, even as demand for its blockbuster weight loss drug Zepbound and ...
Boehringer Ingelheim’s FIBRONEER-ILD phase III study of nerandomilast to treat progressive pulmonary fibrosis meets primary endpoint: Ingelheim, Germany Wednesday, February 12, ...
Parasites are an often-overlooked threat in pet care, especially for cats, as infestations can cause serious health issues ...
The increasing demand for gene therapy and CRISPR technology increases the genome engineering.Dublin, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Introspective Market Research is pleased to announce the ...
Boehringer Ingelheim (BI) has announced positive top-line results from a late-stage study of its investigational ...
Nerandomilast, an oral phosphodiesterase 4B inhibitor, hit the primary endpoint in a Phase III trial in progressive pulmonary ...
Use of DOACs in patients with ICH and AF resulted in a remarkable reduction in ischemic stroke, but that benefit was partially offset by an increase in ICH recurrence.
Boehringer will leverage ExpressionEdits' Genetic Syntax Engine which generates optimized introns to increase protein expression.
Topline data from FIBRONEERâ„¢-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...
Novartis, Eli Lilly and more put on their deal-making caps, Bristol Myers Squibb targets $2 billion in savings through 2027, sales continue to soar for Lilly and Novo Nordisk’s GLP-1s and Regeneron ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback